Ampersand Capital Partners invests in GeneWerk GmbH

On September 21, 2020, Ampersand Capital Partners invested in GeneWerk GmbH, a life science company in Germany.

Deal at a glance

AnnouncedSeptember 21, 2020 TypeGrowth Capital TargetGeneWerk GmbH Buyer Ampersand Capital Partners SectorLife Science LocationGermany ValueNot disclosed

Target company

GeneWerk GmbH

Germany

Life Sciencesector

1962founded

Activestatus

View the company profile →

Buyer

Ampersand Capital Partners

Private equity firm · 76 deals on record

22nd transaction in life science
2nd transaction in Germany

76deals, all time

32in this sector

2022latest

Members only

Contact details at the buyers and sellers

The full deal history of every party

Co-investors and the other advisors on this deal

Deal value and revenue or EBITDA multiples

Related deals

Syft Technologies Ltd.Same lead buyer · Apr 2022

BioEcho Life Sciences GmbHSame lead buyer · Mar 2022

Tubulis GmbHSame sector and country · Apr 2026

STADA Arzneimittel AGSame sector and country · Mar 2026

Tubulis GmbHSame sector and country · Mar 2024

Questions about this deal

Who acquired GeneWerk GmbH?Ampersand Capital Partners invested in GeneWerk GmbH on September 21, 2020.

What type of deal was it?It was a growth capital in the life science sector in 2020.

See the full picture on AcquityDataContacts, full deal histories, co-investors and deal values. Free for a day with your Google account, no card needed.

Try it free

Data updated daily on AcquityData (Acquity Data).